ScripI met the management of InterMune Inc. almost 20 years ago when it was a mid-sized US biotechnology company that had three approved products, two of them interferons. Virtually all of InterMune’s re
Medtech Insight“Digital is no longer a vertical, it cuts across all sectors. It is a horizontal.” Andy Fish, AdvaMed's chief strategy officer, was telling the press in late fall 2019 that medtech companies will come
In Vivo“AI will change the world of health care.” So said Siemens Healthineers AG CFO Jochen Schmitz, addressing a room full of investors at the Jefferies Global Healthcare Conference in November 2019. The
In VivoIs there a harder problem in science than diagnosing and treating forms of dementia? If it was a simple solution, it would have been cracked by now, said Alison Howie, chief commercial officer of neur